Lenalidomid SUN 10 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lenalidomid sun 10 mg kapsel, hård

sun pharmaceutical industries europe b.v. - lenalidomid - kapsel, hård - 10 mg - laktosmonohydrat hjälpämne; lenalidomid 10 mg aktiv substans

Lenalidomid SUN 2,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lenalidomid sun 2,5 mg kapsel, hård

sun pharmaceutical industries europe b.v. - lenalidomid - kapsel, hård - 2,5 mg - laktosmonohydrat hjälpämne; lenalidomid 2,5 mg aktiv substans

Lenalidomid SUN 7,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lenalidomid sun 7,5 mg kapsel, hård

sun pharmaceutical industries europe b.v. - lenalidomid - kapsel, hård - 7,5 mg - laktosmonohydrat hjälpämne; lenalidomid 7,5 mg aktiv substans

Lenalidomid Cipla 20 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lenalidomid cipla 20 mg kapsel, hård

cipla europe nv - lenalidomid - kapsel, hård - 20 mg - propylenglykol hjälpämne; laktos (vattenfri) hjälpämne; lenalidomid 20 mg aktiv substans

Lenalidomide Teva 7,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lenalidomide teva 7,5 mg kapsel, hård

teva b.v. - lenalidomidhydrokloridmonohydrat - kapsel, hård - 7,5 mg - propylenglykol hjälpämne; lenalidomidhydrokloridmonohydrat 9,075 mg aktiv substans

Lenalidomide Teva 10 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lenalidomide teva 10 mg kapsel, hård

teva b.v. - lenalidomidhydrokloridmonohydrat - kapsel, hård - 10 mg - propylenglykol hjälpämne; lenalidomidhydrokloridmonohydrat 12,1 mg aktiv substans

Lenalidomide Teva 20 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lenalidomide teva 20 mg kapsel, hård

teva b.v. - lenalidomidhydrokloridmonohydrat - kapsel, hård - 20 mg - propylenglykol hjälpämne; lenalidomidhydrokloridmonohydrat 24,2 mg aktiv substans

Lenalidomide Teva 2,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lenalidomide teva 2,5 mg kapsel, hård

teva b.v. - lenalidomidhydrokloridmonohydrat - kapsel, hård - 2,5 mg - propylenglykol hjälpämne; lenalidomidhydrokloridmonohydrat 3,025 mg aktiv substans

Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) Europeiska unionen - svenska - EMA (European Medicines Agency)

lenalidomide krka d.d. novo mesto (previously lenalidomide krka)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunsuppressiva - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Lenalidomide Krka d.d. Europeiska unionen - svenska - EMA (European Medicines Agency)

lenalidomide krka d.d.

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunsuppressiva - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) är indicerat för behandling av vuxna patienter med tidigare obehandlat multipelt myelom som inte är berättigade till transplantation. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).